Collins Helen Louise

SEC source: 0000950170-25-083041 · ownership.xml · derivative · entry 1

Collins Helen Louise · CIK 0001701247 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,500

Underlying: Common Stock · 28,500 shares

Expires 2035-06-04

F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant.

SEC source: 0001415889-25-003509 · form4-02102025_100231.xml · derivative · entry 1

Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,000

Underlying: Common Stock · 171,000 shares

Expires 2035-02-06

F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 6, 2026 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0001415889-24-025499 · form4-10222024_081038.xml · derivative · entry 3

Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 266,268

Underlying: Common Stock · 816 shares

Expires 2031-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F3 · derivative.exercise_date: The option, originally for 287,084 shares, vested as to one-fourth of the shares on June 17, 2022, and the remainder vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-24-025499 · form4-10222024_081038.xml · nonDerivative · entry 2

Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

SEC source: 0001415889-24-025499 · form4-10222024_081038.xml · nonDerivative · entry 1

Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 816

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

SEC source: 0000905148-24-001682 · form4.xml · derivative · entry 1

Collins Helen Louise · CIK 0001701247 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,642

Underlying: Common Stock · 45,642 shares

Expires 2034-06-06

F1 · derivative.exercise_date: These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.

SEC source: 0000950170-24-070697 · ownership.xml · derivative · entry 1

Collins Helen Louise · CIK 0001701247 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,000

Underlying: Common Stock · 26,000 shares

Expires 2034-06-04

F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant.

SEC source: 0001415889-24-010823 · form4-04152024_110437.xml · derivative · entry 3

Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 267,084

Underlying: Common Stock · 20,000 shares

Expires 2031-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F3 · derivative.exercise_date: The option, originally for 287,084 shares, vested as to one-fourth of the shares on June 17, 2022, and the remainder vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-24-010823 · form4-04152024_110437.xml · nonDerivative · entry 2

Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

SEC source: 0001415889-24-010823 · form4-04152024_110437.xml · nonDerivative · entry 1

Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

SEC source: 0001415889-24-004012 · form4-02162024_010221.xml · derivative · entry 1

Collins Helen Louise · CIK 0001701247 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,000

Underlying: Common Stock · 185,000 shares

Expires 2034-02-12

F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 13, 2025 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

SEC source: 0000905148-23-001485 · form4.xml · derivative · entry 1

Collins Helen Louise · CIK 0001701247 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,238

Underlying: Common Stock · 64,238 shares

Expires 2033-11-15

F1 · derivative.exercise_date: 1/36th of these options vest each month over three years, subject to the reporting person's continued service through each applicable vesting date, and subject to 100% acceleration upon a change of control.

SEC source: 0001209191-23-033836 · doc4.xml · derivative · entry 1

Collins Helen Louise · CIK 0001701247 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,000

Underlying: Common Stock · 26,000 shares

Expires 2033-05-30

F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant.

SEC source: 0001209191-23-023676 · doc4.xml · derivative · entry 1

Collins Helen Louise · CIK 0001701247 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,000

Underlying: Common Stock · 206,000 shares

Expires 2033-04-04

F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 23, 2024 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date

SEC source: 0001209191-23-013492 · doc4.xml · derivative · entry 1

Collins Helen Louise · CIK 0001701247 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 287,084

Underlying: Common Stock · 287,084 shares

Expires 2031-06-17

F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock (rounded down to the nearest whole share number), (footnote continued in footnote (3))

F3 · price: (continued from footnote (2)): with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent).

F1 · derivative.exercise_date: One-fourth of the shares subject to the option vested on June 17, 2022, and the remainder vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-038944 · doc4.xml · derivative · entry 1

Collins Helen Louise · CIK 0001701247 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2032-06-20

F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant.

SEC source: 0001209191-21-048540 · doc4.xml · derivative · entry 2

Collins Helen Louise · CIK 0001701247 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,166

Underlying: Common Stock · 19,166 shares

Expires 2031-07-27

F2 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant.

SEC source: 0001209191-21-048540 · doc4.xml · derivative · entry 1

Collins Helen Louise · CIK 0001701247 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,000

Underlying: Common Stock · 46,000 shares

Expires 2031-07-27

F1 · derivative.exercise_date: This option vests in three equal annual installments commencing on the one year anniversary of the date of grant.

SEC source: 0001209191-21-027421 · doc4.xml · derivative · entry 9

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 90,000 shares

Expires not disclosed

F3 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.

F4 · derivative.expiration_date: Not applicable.

SEC source: 0001209191-21-027421 · doc4.xml · derivative · entry 8

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 90,000 shares

Expires not disclosed

F3 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.

F4 · derivative.expiration_date: Not applicable.

SEC source: 0001209191-21-027421 · doc4.xml · derivative · entry 7

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires not disclosed

F3 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.

F4 · derivative.expiration_date: Not applicable.

SEC source: 0001209191-21-027421 · doc4.xml · derivative · entry 6

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 58,000 shares

Expires not disclosed

F3 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.

F4 · derivative.expiration_date: Not applicable.

SEC source: 0001209191-21-027421 · doc4.xml · derivative · entry 5

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires not disclosed

F3 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.

F4 · derivative.expiration_date: Not applicable.

SEC source: 0001209191-21-027421 · doc4.xml · derivative · entry 4

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires not disclosed

F3 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option.

F4 · derivative.expiration_date: Not applicable.

SEC source: 0001209191-21-027421 · doc4.xml · nonDerivative · entry 3

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, each issued and outstanding share of common stock of the Company, par value $0.001 per share ("Common Stock"), was converted into the right to receive $38.00 per share (the "Offer Price") in cash, without interest, minus any applicable withholding taxes.

SEC source: 0001209191-21-027421 · doc4.xml · nonDerivative · entry 2

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,547

F1 · shares: Represents shares of performance-based restricted Common Stock (as defined below) granted to the reporting person on June 24, 2019 (the "Performance Award"). The performance conditions associated with the Performance Award have not yet occurred. Pursuant to the Merger Agreement (as defined below), immediately prior to the effective time of the Merger (as defined below), the Performance Award was deemed to have vested and each share of Common Stock underlying the Performance Award was converted into the right to receive the Offer Price (as defined below) in cash, without interest, minus any applicable withholding taxes.

SEC source: 0001209191-21-027421 · doc4.xml · nonDerivative · entry 1

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,547

SEC source: 0001209191-21-015609 · doc4.xml · nonDerivative · entry 1

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,632

SEC source: 0001209191-21-014644 · doc4.xml · nonDerivative · entry 2

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,790

SEC source: 0001209191-21-014644 · doc4.xml · nonDerivative · entry 1

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,443

SEC source: 0001209191-20-063389 · doc4.xml · derivative · entry 3

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The shares subject to this grant vest upon achievement of certain performance conditions, as further described in the other footnotes to this report.

F3 · shares: Represents 50% of the shares subject to this award, which shares vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company was greater than or equal to $19.43.

F4 · derivative.exercise_date: 50% of the shares subject to this award vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company was greater than or equal to $12.95, and the remaining 50% of the shares subject to this award vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company was greater than or equal to $19.43.

F4 · derivative.expiration_date: 50% of the shares subject to this award vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company was greater than or equal to $12.95, and the remaining 50% of the shares subject to this award vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company was greater than or equal to $19.43.

SEC source: 0001209191-20-063389 · doc4.xml · nonDerivative · entry 2

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,534

SEC source: 0001209191-20-063389 · doc4.xml · nonDerivative · entry 1

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,117

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of performance-based restricted common stock granted to the reporting person on June 24, 2019. These shares vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of Five Prime Therapeutics, Inc. (the "Company") was greater than or equal to $19.43.

SEC source: 0001209191-20-058237 · doc4.xml · derivative · entry 3

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The shares subject to this grant vest upon achievement of certain performance conditions, as further described in the other footnotes to this report.

F3 · shares: Represents 50% of the shares subject to this award, which shares vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company was greater than or equal to $12.95.

F4 · derivative.exercise_date: The remaining shares subject to this award will vest on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company is greater than or equal to $19.43, subject to the reporting person's continued service to the Company through such date; provided that such shares shall automatically expire and be forfeited if such shares have not vested by December 31, 2021.

F4 · derivative.expiration_date: The remaining shares subject to this award will vest on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company is greater than or equal to $19.43, subject to the reporting person's continued service to the Company through such date; provided that such shares shall automatically expire and be forfeited if such shares have not vested by December 31, 2021.

SEC source: 0001209191-20-058237 · doc4.xml · nonDerivative · entry 2

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,117

SEC source: 0001209191-20-058237 · doc4.xml · nonDerivative · entry 1

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,156

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of performance-based restricted common stock granted to the reporting person on June 24, 2019. These shares vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of Five Prime Therapeutics, Inc. (the "Company") was greater than or equal to $12.95.

SEC source: 0001209191-20-048041 · doc4.xml · nonDerivative · entry 1

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,156

SEC source: 0001209191-20-020592 · doc4.xml · nonDerivative · entry 1

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,983

SEC source: 0001209191-20-013272 · doc4.xml · nonDerivative · entry 4

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,810

SEC source: 0001209191-20-013272 · doc4.xml · nonDerivative · entry 3

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,091

SEC source: 0001209191-20-013272 · doc4.xml · derivative · entry 6

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2030-02-23

F4 · derivative.exercise_date: The shares underlying the option vest at a rate of one forty-eighth (1/48) per month following February 24, 2020, provided the reporting person provides services to the Company through each such date.

SEC source: 0001209191-20-013272 · doc4.xml · derivative · entry 5

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2030-02-23

F3 · derivative.exercise_date: Represents a retention equity incentive award consisting of options to purchase shares of the Company's common stock. One-fourth (1/4) of the shares underlying this option will vest on February 24, 2021, and the remainder of the shares underlying this option vest at a rate of one forth-eighth (1/48) per month thereafter, provided the reporting person provides services to the Company through each such date.

SEC source: 0001209191-20-013272 · doc4.xml · nonDerivative · entry 2

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,953

F2 · shares: Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 24, 2021, 2022 and 2023, provided the reporting person provides services to the Company through each such date.

SEC source: 0001209191-20-013272 · doc4.xml · nonDerivative · entry 1

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,953

F1 · shares: Represents a retention equity incentive award consisting of shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 24, 2021, 2022 and 2023, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date.

SEC source: 0001209191-20-007293 · doc4.xml · nonDerivative · entry 1

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,953

SEC source: 0001209191-19-048073 · doc4.xml · nonDerivative · entry 1

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,298

SEC source: 0001209191-19-047176 · doc4.xml · derivative · entry 2

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2029-08-19

F2 · derivative.exercise_date: The shares underlying the option vest at a rate of one forty-eighth (1/48th) per month following August 20, 2019, provided the reporting person provides services to the Company through each such date.

SEC source: 0001209191-19-047176 · doc4.xml · nonDerivative · entry 1

Collins Helen Louise · CIK 0001701247 · EVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,794

F1 · shares: Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of August 20, 2020, 2021 and 2022, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date.

SEC source: 0001209191-19-039101 · doc4.xml · derivative · entry 1

Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires not disclosed

F1 · derivative.exercise_price: These shares will vest upon achievement of certain performance conditions, as further described in Footnote 2.

F2 · derivative.exercise_date: (i) 50% of the shares subject to this award will vest on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of Five Prime Therapeutics, Inc. (the "Company") is greater than or equal to $12.95, provided that such shares shall automatically expire and be forfeited if such shares have not vested by December 31, 2020; and (ii) 50% of the shares subject to this award will vest on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company is greater than or equal to $19.43, provided that such shares shall automatically expire and be forfeited if such shares have not vested by December 31, 2021; in each case, subject to the reporting person's continued service to the Company through each such date.

F2 · derivative.expiration_date: (i) 50% of the shares subject to this award will vest on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of Five Prime Therapeutics, Inc. (the "Company") is greater than or equal to $12.95, provided that such shares shall automatically expire and be forfeited if such shares have not vested by December 31, 2020; and (ii) 50% of the shares subject to this award will vest on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company is greater than or equal to $19.43, provided that such shares shall automatically expire and be forfeited if such shares have not vested by December 31, 2021; in each case, subject to the reporting person's continued service to the Company through each such date.

SEC source: 0001209191-19-014255 · doc4.xml · nonDerivative · entry 2

Collins Helen Louise · CIK 0001701247 · SVP and Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,794